Clinical trials: Atopic Eczema
Dermatitis, Atopic
An Observational Study to Gather Real-World User Feedback on DIPROBASE® Advanced Eczema Cream in Adults and Children With Eczema or Dry Skin
This is an observational study which means only data are collected from participants about their experience and symptoms, who received their usual treatment without any intervention from the study sponsor.
- Trial name
- NCT06747897
- Testing
- MINERAL OIL + PETROLATUM (DIPROBASE® Advanced Eczema Cream, BAY987534, UI 1613882)
- Where
- United Kingdom
- Volunteers
- 300 people
- Sponsor
- Bayer
Atopic Dermatitis
Effect of OC000459 on Moderate to Severe Atopic Dermatitis
The purpose of this study is to determine whether OC000459 is in reducing disease severity and preventing flares in people with moderate to severe atopic dermatitis (AD).
- Trial name
- NCT02002208
- Testing
- OC000459
- Where
- United Kingdom
- Volunteers
- 142 people
- Sponsor
- Atopix Therapeutics, Ltd.
Atopic Dermatitis
Evalution the Safety and Efficacy in Atopic Dermatitis Patients
A multi-center, open, long-term follow-up study to evaluate the efficacy and safety of FURESTEM-AD inj. in patients with moderate to severe chronic atopic dermatitis: 5-year results from the K0102 extension study
- Trial name
- NCT03962387
- Testing
- Not applicable(observational study)
- Where
- South Korea
- Volunteers
- 98 people
- Sponsor
- Kang Stem Biotech Co., Ltd.
Atopic Dermatitis
A Phase 2 Study of PH-10 for the Treatment of Atopic Dermatitis
PH-10 is a formulation of rose bengal disodium (RB) for topical administration to the skin. PH-10 is capable of undergoing photochemical reactions when activated by ambient light.
- Trial name
- NCT00690807
- Testing
- PH-10
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Provectus Pharmaceuticals
Dermatitis, Atopic
Study to Evaluate the Use of RHT-3201 in SCORAD Reduction in Young Patients With Atopic Dermatitis
The study's objective is to confirm that RHT-3201 reduces the signs and symptoms of moderate atopic dermatitis determined by SCORAD, in patients aged 1 to 12 years, as compared to placebo.
- Trial name
- NCT03907228
- Testing
- RHT-3201
- Where
- South Korea
- Volunteers
- 102 people
- Sponsor
- IlDong Pharmaceutical Co Ltd
Atopic Dermatitis
Evaluate the Efficacy and Safety of XKH001 Injection in Patients With Moderate-to-Severe Atopic Dermatitis
This study will be a multicenter, randomized, double-blinded, placebo-controlled clinical study. It is planned to enroll 120 adult patients with moderate-to-severe Atopic Dermatitis whose disease cannot be adequately controlled…
- Trial name
- NCT07054736
- Testing
- XKH001 Injection
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Zhejiang Kanova Biopharmaceutical Co., LTD
Atopic Dermatitis
A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis
This study will assess long-term safety and efficacy of Afimkibart (also known as RO7790121) in participants with Atopic Dermatitis (AD) who participated in previous afimkibart clinical trials.
- Trial name
- Velarite-LTE (NCT07223697)
- Testing
- Afimkibart
- Where
- 31 sites in United States, Brazil and 5 more
- Volunteers
- 120 people
- Sponsor
- Hoffmann-La Roche
Dermatitis, Atopic
Tacrolimus Ointment Pharmacokinetics in Infants With Atopic Dermatitis
The purpose of this study is to estimate the systemic exposure to tacrolimus in infants with atopic dermatitis after repeated application of tacrolimus ointment.
- Trial name
- NCT00535691
- Testing
- Tacrolimus Ointment 0.03%
- Where
- 8 sites in Canada, Finland and 3 more
- Volunteers
- 53 people
- Sponsor
- Astellas Pharma Inc
Atopic Dermatitis
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Topical therapies applied over the skin may not be enough to control the AD in trial participants who require systemic…
- Trial name
- Start Up (NCT06461897)
- Testing
- Upadacitinib, Dupilumab
- Where
- 150 sites in United States, Argentina and 24 more
- Volunteers
- 699 people
- Sponsor
- AbbVie
Crohn Disease, Ulcerative Colitis
Expanded Access to Upadacitinib
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to upadacitinib prior to approval by the local regulatory agency. Availability will depend on territory eligibility.
- Conditions
- Crohn Disease, Ulcerative Colitis, Idiopathic Arthritis (Including sJIA, pJIA, or JPsA), Atopic Dermatitis
- Trial name
- NCT04159597
- Testing
- Upadacitinib
- Sponsor
- AbbVie
Prurigo Nodularis
A Randomized Placebo-Controlled Study of the Neurokinin-1 (NK1) Receptor Antagonist Serlopitant Prurigo Nodularis (PN)
The purpose of this study is to demonstrate whether or not VPD-737, an NK1 receptor antagonist is safe and effective for treatment of prurigo nodularis versus placebo.
- Trial name
- NCT02196324
- Testing
- serlopitant
- Where
- 15 sites in Germany
- Volunteers
- 128 people
- Sponsor
- Vyne Therapeutics Inc.
Healthy Volunteer, Hidradenitis Suppurativa
A Single and Multiple Ascending Dose Trial of LT-002-158 Tablets in Healthy Adult Volunteers
LT-002-158 is an oral IRAK4 protein degrader being developed for the treatment of autoimmune disease and inflammation including Hidradenitis Suppurativa and Atopic Dermatitis.
- Conditions
- Healthy Volunteer, Hidradenitis Suppurativa, Atopic Dermatitis
- Trial name
- NCT06082323
- Where
- China
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.
Atopic Dermatitis
Safety and Efficacy of CD5024 0.3% Cream in Subjects With Atopic Dermatitis
Exploratory, multi-centric, randomized, vehicle-controlled, investigator-blind, parallel group study, involved participants with chronic lesions of Atopic Dermatitis (AD) to evaluate the local and systemic safety of CD5024 0.3%…
- Trial name
- NCT03250624
- Testing
- CD5024 0.3% cream
- Where
- 5 sites in Canada
- Volunteers
- 63 people
- Sponsor
- Galderma R&D
Atopic Dermatitis
Comparison of LimpiAD Cream 2.5% Plus Versus Its Vehicle and and a Basic Emollient in Patients With Atopic Dermatitis
The purpose of this clinical trial is to assess the efficacy and tolerability of LimpiAD, a medical device in the formulation of a 2.5% Plus cream, versus the Vehicle of LimpiAD 2,5% Plus cream, and versus a basic emollient in…
- Trial name
- NCT05984420
- Testing
- LimpiAD 2,5% plus cream, Vehicle, Emollient
- Where
- 5 sites in Italy
- Volunteers
- 200 people
- Sponsor
- Aileens Pharma SRL
Atopic Dermatitis
A Safety and Efficacy of DRM02 in Subjects With Atopic Dermatitis
The purpose of this study is to determine whether DRM02 is safe and effective in the treatment of atopic dermatitis when applied twice daily for 6 weeks.
- Trial name
- NCT01993420
- Testing
- DRM02, Vehicle
- Where
- 2 sites in Canada
- Volunteers
- 21 people
- Sponsor
- Dermira, Inc.
Dermatitis, Atopic
A Comparison Study Between Protopic (Tacrolimus) Ointment and Elidel (Pimecrolimus) Cream in Treating Subjects With Atopic Dermatitis
A study to compare efficacy of Protopic Ointment to that of Elidel Cream in treating patients with Atopic Dermatitis
- Trial name
- NCT00666302
- Testing
- tacrolimus ointment, pimecrolimus cream
- Where
- 15 sites in United States, Canada
- Volunteers
- 413 people
- Sponsor
- Astellas Pharma Inc
Atopic Dermatitis
The Effect of Isosorbide Diesters Based Moisturizer on Skin Health
The overall objective of this study is to assess how a natural ingredient, isosorbide diesters (IDEAS), works in association with colloidal oatmeal for eczema.
- Trial name
- NCT04831892
- Testing
- Moisturizer Containing Isosorbide Diesters and Colloidal Oatmeal, Moisturizer containing Colloidal Oatmeal only
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Integrative Skin Science and Research
Atopic Dermatitis
Lebrikizumab Pen Ease of Use in Participants With Atopic Dermatitis
The purpose of this study is to assess the ease of use of the lebrikizumab pen. Participants will use a practice pad to simulate administration of a dose.
- Trial name
- NCT06444165
- Testing
- Lebrikizumab Pen
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Eli Lilly and Company
Atopic Dermatitis (AD)
A Phase 1/1b Study to Evaluate Safety, Tolerability and Pharmacokinetics of ZL-1503 in Healthy Volunteers and Participants With Moderate to Severe Atopic Dermatitis
This is a phase 1/1b randomized, double blind, placebo-controlled, single dose escalation (SAD) and multiple dose escalation (MAD) study to evaluate the safety, tolerability, and pharmacokinetics (PK) of ZL-1503 in healthy…
- Trial name
- NCT07235384
- Testing
- ZL-1503
- Where
- 12 sites in Australia, China and 1 more
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Zai Lab (Shanghai) Co., Ltd.
Atopic Dermatitis
Open-Label Extension Study of Upadacitinib in Adult Participants With Moderate to Severe Atopic Dermatitis
This is a study for adults (18-75 years) who have successfully completed treatment either with Dupilumab or with Upadacitinib in the study M16-046.
- Trial name
- NCT04195698
- Testing
- Upadacitinib
- Where
- 116 sites in United States, Australia and 20 more
- Volunteers
- 475 people
- Sponsor
- AbbVie